The FDA has approved belantamab mafodotin-blmf as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody.
The DREAMM-2 trial, which showed that belantamab mafodotin elicited an overall response rate (ORR) of 31% in patients with relapsed/refractory multiple myeloma who received the treatment at the recommended 2.5 mg/kg dose.
In patients who received belantamab mafodotin at 3.4 mg/kg, the ORR was 34%.
Overall, the median duration of response (DOR) was not reached.
The median PFS was 2.9 months and 4.9 months in the 2.5-mg/kg and 3.4-mg/kg cohorts, respectively.
Overall survival data were immature at the time of the analysis.
Adverse events included: keratopathy, thrombocytopenia and anemia.
2.5 mg/kg is the recommended dose.